Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INSPIRE: Durvalumab with Chemoradiation in Stage III Node-Positive Bladder Cancer
NCT04216290Phase 2Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Mar 2021
- Primary completion
- Feb 2026
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of durvalumab in bladder urothelial carcinoma, sponsored by National Cancer Institute. Started Mar 2021; status: active, not recruiting.
02
Drugs
durvalumab
03
Conditions
bladder urothelial carcinoma
Beyond the preview
Go deeper on NCT04216290.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04216290.